Jaime-Fagundo JC, Arencibia-Núñez A, Gutiérrez-Díaz A, Ramón-Rodríguez L, Díaz-Durán C, Serrano-Mirabal J, Sarduy-Sáez S, Pavón-Morán V

Idioma: Español
Referencias bibliográficas: 36
Paginas:
Archivo PDF: 219.23 Kb.

RESUMEN

Las urgencias que pueden surgir durante la evolución de las enfermedades hematológicas son diversas, tanto por el comportamiento de la enfermedad de base como por el momento en que se presentan. Pueden ser la primera manifestación de la enfermedad o aparecer en el curso de su evolución, y sus secuelas pueden ser menores si se diagnostican y tratan adecuadamente. Se hace una revisión de algunas de las alteraciones metabólicas y leucocitarias más frecuentes que se pueden presentar en el paciente oncohematológico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol. 2000 Jun;27(3):322- 34.

2. Solimando DA. Overview of hypercalcemia of malignancy. Am J Health Syst Pharm. 2001 Nov;15(8):34-7.

3. Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology. 2005 Aug;146(8):3235-43.

4. Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, et al. Identification and characterization of a potent, selective and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23;275(25):190-8.

5. Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999.

6. Terpos E, Sezer O, Croucher P. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009 Aug;20(8):1303-17.

7. Dunford JE, Rogers MJ, Ebetino FH. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res. 2006 May;21(5):684-94.

8. Rosen LS, Gordon D, Antonio BS, Kaminski M, Howell A, Belch A, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001 Sep-Oct;7(5):377-87.

9. Kraj M, Poglód R, Maj S, Pawlikowski J, Sokolowska U, Szczepanik J. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Pol Pharm. 2002 Nov-Dec;59(6):478-82.

10. Céspedes-Quevedo MC, Ropero-Toirac R, Torres-Linares M. Estimación del filtrado glomerular por cálculo, utilizando la creatinina sérica. Bol Cientif ISCM (Santiago de Cuba). 1994;6(1):159-68.

11. Madan J, Arrowsmith R. Complications of Hematopoietic Neoplasms. En: Greer JP, Lukens JN eds. Wintrobe's Clinical Hematology. 11th ed. Philadelphia: Lippincott Williams & Wilkins Publishers; 2003.

12. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis Blood. 2001 May 15;97(10):2998-3003.

13. Rizzardini C, Espinoza X. Urgencias oncológicas. Rev Ped Elec (en línea) 2005;2(2):25-32. ISSN 0718-0918. Disponible en: http://www.revistapediatria.cl/vol2num2/pdf /8_urgencias_oncologicas.pdf

14. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008 Jun 1;26(16):2767-78.

15. Hochberg J, Cairo M. Tumor lysis syndrome: current perspective. Haematologica. 2008 Jan;93(1):67-74.

16. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006 Aug;3(8):438-47.

17. Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008 Dec;93(12):1877-85.

18. Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, et al. Hyperleukocytic leukemias and leukostasis: A review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000 Sep;39(1-2):1-18.

19. Litchmann MA, Heal J, Rowe JM. Hyperleukocytic leukemia: rheological and clinical features and management. Baillieres Clin Haematol. 1987 Sep;1(3):725-46.

20. Doerschuck CM, Quinlan WM, Doyle NA, Bullard DC, Vestweber D, Jones ML, et al. The roles of P-selectin and ICAM-I in acute lung injury as determined using anti-adhesion molecule antibodies and mutant mice. J Immunol. 1996 Nov 15;157(10):4609-14.

21. Kamasaka T, Quinlan WM, Doyle NA, Condon TE , Sligh J, Takei F, et al. The role of ICAM-1 in endotoxin-induced pneumonia evaluated using ICAM- 1 antisense, anti-ICAM-1 antibodies and ICAM-1 mutant mice. J Clin Invest. 1996 May 15;97(10):2362-9.

22. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001 Apr 1;97(7):2121-9.

23. McKee LC, Collins R D. Intravascular thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine (Baltimore). 1974 Nov;53(6):463-78.

24. Grund EM, Armitage JO, Bums CP. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Intern Med. 1977 Sep;137(9):1246-7.

25. Bug G, Anargyrou K, Tonn T, Bialleck H, Seifried E, Hoelzer D, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007 Oct;47(10):1843-50.

26. Karp D, Beck JR, Comell CJ Jr. Chronic granulocytic leukemia with respiratory distress. Efficacy of emergency leukapheresis. Arch Intern Med. 1981 Sep;141(10):1353-4.

27. Filep JG, Delalandre A, Payette Y, Foldes-Filep E. Glucocorticoid receptor regulates the expression of L-selectin and CDllICD18 on human neutrophils. Circulation. 1997 Jul 1;96(1):295-301.

28. Chang MC, Chen TY, Tang JL, Lan YJ, Chao TY, Chiu CF, et al. Leukapheresis and cranial irradiation in patients with Hyperleukocytic acute myeloid leukemia: No impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007 Nov;82(11):976-80.

29. Gómez E, Roncero C, De Pablo J, Rovira M. Síndrome de hiperviscosidad y alteraciones mentales. Acta Esp Psiquiatr. 2000;28(4):263-6.

30. Foerster J. Discrasias de células plasmáticas: consideraciones generales. Hematología Clínica de Wintrobe. 9na. ed. Buenos Aires: Editorial Intermédica; 1995. pp. 1909-23.

31. Seth R, Bhat AS. Management of Common Oncologic Emergencies. Indian J Pediatr. 2011 Mar 12. [Epub ahead of print] DOI 10.1007/s12098-011-0381-5.

32. Mullen E, Méndez N. Hyperviscosity syndrome in patients with multiple myeloma. Oncol Nurs Forum. 2008 May;35(3):350-2.

33. Zojan N, Ludwig H. Hematological emergencies. Ann Oncol. 2007 Jan;18(1):45-8.

34. Ballestri M, Ferrari F, Magistroni R, Mariano M, Ceccherelli GB, Milanti G, et al. Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guideline study. Ann Ist Super Sanita. 2007;43(2):171-5.

35. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia. 2009 Mar;23(3):449-56.

36. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009 Aug;9(4):278-88.